Clinical Trial

Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study evaluates the efficacy and safety of adding the SGLT-2 inhibitor DA5221-T to the combination therapy of DA5221-B1 and the DPP-4 inhibitor DA5221-B2 in patients with type 2 diabetes who have inadequate blood glucose control. The study focuses on assessing the effectiveness and safety of the triple combination therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-26.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-11-16
Trial Details
NCT Number NCT06290349
Lead Sponsor Dong-A ST Co., Ltd.
Conditions Type 2 Diabetes
Enrollment 174 participants
Start Date 2024-04-01
Primary Completion 2025-09-05 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-19